- Home
- TD vs SNY Comparison
TD vs SNY Comparison
Compare TD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TD
- SNY
- Stock Information
- Founded
- TD 1855
- SNY 1994
- Country
- TD Canada
- SNY France
- Employees
- TD N/A
- SNY N/A
- Industry
- TD
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- TD
- SNY Health Care
- Exchange
- TD Nasdaq
- SNY Nasdaq
- Market Cap
- TD 109.9B
- SNY 123.6B
- IPO Year
- TD N/A
- SNY N/A
- Fundamental
- Price
- TD $63.04
- SNY $52.13
- Analyst Decision
- TD Buy
- SNY Buy
- Analyst Count
- TD 2
- SNY 2
- Target Price
- TD $83.50
- SNY $62.50
- AVG Volume (30 Days)
- TD 1.9M
- SNY 3.1M
- Earning Date
- TD 05-22-2025
- SNY 04-24-2025
- Dividend Yield
- TD 4.67%
- SNY 3.09%
- EPS Growth
- TD N/A
- SNY 39.56
- EPS
- TD 3.26
- SNY 5.45
- Revenue
- TD $36,873,924,749.00
- SNY $48,817,552,946.00
- Revenue This Year
- TD $9.51
- SNY $5.35
- Revenue Next Year
- TD $3.99
- SNY $6.69
- P/E Ratio
- TD $19.36
- SNY $9.56
- Revenue Growth
- TD 0.91
- SNY N/A
- 52 Week Low
- TD $51.25
- SNY $45.80
- 52 Week High
- TD $64.91
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- TD 60.71
- SNY 44.93
- Support Level
- TD $55.00
- SNY $51.67
- Resistance Level
- TD $63.98
- SNY $55.73
- Average True Range (ATR)
- TD 0.74
- SNY 0.90
- MACD
- TD 0.07
- SNY 0.10
- Stochastic Oscillator
- TD 69.27
- SNY 31.69
About TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 55% of its revenue from Canada and has dominant market share in nearly all banking products and services. TD has around 40% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.